Stock BIO.B BIO-RAD LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bio-Rad Laboratories, Inc. Nyse

Equities

BIO.B

US0905721082

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 21:15:00 10/05/2024 BST 		5-day change 1st Jan Change
279.9 USD 0.00% Intraday chart for Bio-Rad Laboratories, Inc. 0.00% -12.71%
05-08 UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating MT
05-08 RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 11,075 17,345 22,439 12,460 9,399 8,033 - -
Enterprise Value (EV) 1 10,400 17,345 22,439 11,868 8,992 7,359 7,206 6,993
P/E ratio - 4.62 x 5.38 x - -14.8 x 27.4 x 28.2 x 24.7 x
Yield - - - - - - - -
Capitalization / Revenue 4.79 x 6.81 x 7.68 x 4.45 x 3.52 x 3.02 x 2.87 x 2.79 x
EV / Revenue 4.5 x 6.81 x 7.68 x 4.24 x 3.37 x 2.77 x 2.58 x 2.43 x
EV / EBITDA 26.7 x 32.3 x 33.1 x 17.8 x 16.8 x 15.6 x 13.8 x 12.6 x
EV / FCF 28,939,110 x 36,407,140 x 41,886,472 x 126,657,378 x 23,981,479 x - - -
FCF Yield 0% 0% 0% 0% 0% - - -
Price to Book - - - 1.27 x 1.05 x 0.86 x 0.83 x 0.8 x
Nbr of stocks (in thousands) 29,935 29,831 29,918 29,824 29,145 28,525 - -
Reference price 2 370.0 582.9 755.6 420.5 322.9 282.0 282.0 282.0
Announcement Date 13/02/20 11/02/21 10/02/22 16/02/23 15/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,312 2,546 2,923 2,802 2,671 2,661 2,794 2,877
EBITDA 1 389.6 537.4 677.5 667.9 535.9 470.2 522.6 555.2
EBIT 1 278.5 426.6 571.2 524 378.9 347 394.4 434
Operating Margin 12.05% 16.76% 19.54% 18.7% 14.19% 13.04% 14.11% 15.08%
Earnings before Tax (EBT) 1 - 4,908 5,438 - -850.1 376.5 366 423
Net income 1 - 3,806 4,246 -3,628 -637.3 294 285 326
Net margin - 149.52% 145.28% -129.45% -23.86% 11.05% 10.2% 11.33%
EPS 2 - 126.2 140.6 - -21.82 10.30 10.01 11.42
Free Cash Flow 359.4 476.4 535.7 93.7 374.9 - - -
FCF margin 15.55% 18.71% 18.33% 3.34% 14.04% - - -
FCF Conversion (EBITDA) 92.24% 88.64% 79.08% 14.03% 69.97% - - -
FCF Conversion (Net income) - 12.52% 12.62% - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 13/02/20 11/02/21 10/02/22 16/02/23 15/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 747 732.8 700.1 691.1 680.8 730.3 676.8 681.1 632.1 681.2 610.8 640.8 669.4 733.2 649.3
EBITDA 1 179.3 140 179.5 156.2 132.3 156.5 148.5 137.9 112.7 136.8 108.5 93 119.1 154.6 114.1
EBIT 1 138.5 112.8 153.8 129.9 105.8 127 84.17 107.9 81.59 105.2 59.01 64.91 88.84 121.9 82.69
Operating Margin 18.54% 15.39% 21.97% 18.79% 15.54% 17.4% 12.44% 15.85% 12.91% 15.45% 9.66% 10.13% 13.27% 16.63% 12.73%
Earnings before Tax (EBT) - - - - - - - -1,500 - - - - - - -
Net income - - - - - 827.7 - -1,162 - 349.7 - - - - -
Net margin - - - - - 113.34% - -170.64% - 51.34% - - - - -
EPS - - - - -5.520 - - -39.59 - - - - - - -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 28/10/21 10/02/22 28/04/22 28/07/22 27/10/22 16/02/23 04/05/23 03/08/23 26/10/23 15/02/24 07/05/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 675 - - 592 408 674 828 1,040
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 359 476 536 93.7 375 - - -
ROE (net income / shareholders' equity) - 48.7% 36.1% 3.71% 3.76% 3.18% 3.11% 3.57%
ROA (Net income/ Total Assets) - 36.3% 27.6% - - 2.3% 2.2% 2.4%
Assets 1 - 10,491 15,374 - - 12,783 12,955 13,583
Book Value Per Share 2 - - - 332.0 307.0 327.0 340.0 354.0
Cash Flow per Share - - - 6.530 - - - -
Capex 1 98.5 98.9 121 101 - 138 144 142
Capex / Sales 4.26% 3.89% 4.13% 3.6% - 5.19% 5.15% 4.95%
Announcement Date 13/02/20 11/02/21 10/02/22 16/02/23 15/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bio-Rad Laboratories, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
282 USD
Average target price
393.8 USD
Spread / Average Target
+39.65%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.84% 182B
MEDTRONIC PLC Stock Medtronic plc
+0.56% 110B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.35% 68.11B
DEXCOM, INC. Stock DexCom, Inc.
+2.39% 50.53B
CENCORA, INC. Stock Cencora, Inc.
+9.36% 44.8B
HOYA CORPORATION Stock Hoya Corporation
+2.70% 40.7B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+3.43% 26.53B
TERUMO CORPORATION Stock Terumo Corporation
+13.67% 25.02B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-0.32% 24.96B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. BIO Stock
  4. BIO.B Stock
  5. Financials Bio-Rad Laboratories, Inc.